The association between homocysteine and myocardial infarction is independent of age, sex, blood pressure, cholesterol, smoking and markers of inflammation: The Glasgow Myocardial Infarction Study

Blood Coagulation and Fibrinolysis

Volumn 17, Issue 1, 2006, Pages 1-5

  Woodward, Mark ^a   Rumley, Alan ^b   Rumley, Ann ^c   Rumley, Christopher ^c   Lewington, Sarah ^d   Morrison, Caroline E ^e   Lowe, Gordon D O ^b,c  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

^c UNIVERSITY OF GLASGOW   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e NHS GREATER GLASGOW AND CLYDE   (United Kingdom)

Author keywords

Homocysteine; Inflammation; Myocardial infarction

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; FIBRINOGEN; HOMOCYSTEINE; INTERLEUKIN 6;

ADULT; AGE; ARTERY WALL; ARTICLE; BLOOD PRESSURE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GEOGRAPHIC DISTRIBUTION; HEART INFARCTION; HUMAN; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK; RISK FACTOR; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE;

EID: 31644451877     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mbc.0000195919.71950.f7     Document Type: Article

References (30)

1. Engman M. Homocysteinemia: new information about an old risk factor for vascular disease. J Insur Med 1998; 30:231-236.
2. Carmel R, Jacobsen DW, editors. Homocysteine in health and disease. Cambridge: Cambridge University Press; 2000.
3. Homocysteine Lowering Trialists' Collaboration. Lowering blood homocysteine with folic acid based supplements: meta-analysis of randomised trials. BMJ 1998; 316:894-898.
4. Bautista LE, Arenas IA, Penuela A, Martinez LX. Total plasma homocysteine level and risk of cardiovascular disease: a meta-analysis of prospective cohort studies. J Clin Epidemiol 2002; 55:882-887.
5. The Homocysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke. JAMA 2002; 288:2015-2023.
6. Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002; 325:1202.
7. Ueland PM, Refsum H, Stableer SP, Malinow MR, Andersson A, Allen RH. Total homocysteine in plasma or serum: methods and clinical applications. Clin Chem 1993; 39:1764-1779.
8. Klerk M, Verhoef P, Clarke R, Henk JB, Kok FJ, Schouten EG. MTHFR 677C→T polymorphism and risk of coronary heart disease. JAMA 2002; 288:2023-2032.
9. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease. JAMA 1998; 279:1477-1482.
10. Fibrinogen Studies Collaboration. Collaborative meta-analysis of prospective observational studies of plasma fibrinogen and cardiovascular disease. Eur J Cardiovasc Prev Rehabil 2004; 11:9-17.
11. Danesh J, Wheeler JG, Hirshfield GM, Eda S, Eiriksdottir G, Rumley A, et al. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med 2004; 350:1387-1397.
12. Ridker PM, Rifai N, Stampfer MJ, Hennekens CH. Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men. Circulation 2000; 101:1767-1772.
13. Lowe GDO, Rumley A, McMahon AD, Ford I, O'Reilly DStJ, Packard CJ, for the West of Scotland Coronary Prevention Study Group, Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease. Arterioscler Thromb Vasc Biol 2004; 24:1529-1534.
14. Boekholdt SM, Peters RJG, Hack E, Day NE, Luben R, Bingham SA, et al. IL-8 plasma concentrations and the risk of future coronary artery disease in apparently healthy men and women. The EPIC-Norfolk Prospective Population Study. Arterioscler Thromb Vasc Biol 2004; 24:1503-1508.
15. Poddar R, Sivasubramanian N, DiBello PM, Robinson K, Jacobsen DW. Homocysteine induces expression and secretion of monocyte chemoattractant protein-1 and interleukin-8 in human aortic endothelial cells: Implications for vascular disease. Circulation 2001; 103:2717-2723.
16. Lowe GDO, Woodward M, Rumley A, Morrison CE, Niewenhuizen W. Associations of plasma fibrinogen assays, C-reactive protein and interleukin-6 with previous myocardial infarction. J Thromb Haemost 2003; 1:2312-2316.
17. Morrison C, Woodward M, Leslie W, Tunstall-Pedoe H. Effect of socioeconomic group on incidence of, management of, and survival after myocardial infarction and coronary death: analysis of community coronary event register. BMJ 1997; 314:541-546.
18. Tunstall-Pedoe H, for the WHO MONICA Project. The World Health Organisation MONICA Project (Monitoring Trends and Determinants in Cardiovascular Disease): a major international collaboration. J Clin Epidemiol 1988; 41:105-113.
19. Woodward M. Epidemiology; study design and data analysis. 2nd ed. Boca Raton, FL: Chapman and Hall/CRC Press; 2005.
20. Gomes E, Duarte R, Reis RP, Candido A, Cardim N, Correia MJ, et al. Homocysteine increase after acute myocardial infarction - can it explain the differences between case-control and cohort studies? Rev Port Cardiol 2002; 21:575-581.
21. Hultdin J, Thogersen AM, Jansson JH, Nilsson TK, Weinehall L, Hallmans G. Elevated plasma homocysteine: cause or consequence of myocardial infarction? J Intern Med 2004; 256:491-498.
22. Duncan GE, Li SM, Zhou XH. Age and kidney function are the primary correlates of fasting plasma total homocysteine levels in non-diabetic and diabetic adults. Results from the 1999-2002 National Health and Nutrition Examination Survey. Nutr Metab (Lond) 2005; 2 (in press).
23. Weiner DE, Tighiouart H, Stark PC, Amin MG, MacLeod B, Griffith JL, et al. Kidney disease as a risk factor for recurrent cardiovascular disease and mortality. Am J Kidney Dis 2004; 44:198-206.
24. Retterstol L, Paus B, Bohn M, Bakken A, Erikssen J, Malinow MR, Berg K. Plasma total homocysteine levels and prognosis in patients with previous premature myocardial infarction: a 10-year follow-up study. J Intern Med 2003; 253:284-292.
25. Tanne D, Haim M, Goldbourt U, Boyko V, Doolman R, Adler Y, et al. Prospective study of serum homocysteine and risk of ischemic stroke among patients with preexisting coronary heart disease. Stroke 2003; 34:632-636.
26. Cesari M, Cesari M, Zanchetta M, Burlina A, Pedon L, Maiolino G, et al. Hyperhomocysteinemia is inversely related with left ventricular ejection fraction and predicts cardiovascular mortality in high-risk coronary artery disease hypertensives. Arterioscler Thromb Vasc Biol 2005; 25:115-121.
27. Clarke R, Armitage J. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements. Semin Thromb Hemost 2000; 26:341-348.
28. Toole JFM, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJM, et al. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: The Vitamin Intervention for Stroke Prevention (VISP) Randomized Controlled Trial. JAMA 2004; 291:565-575.
29. Lange H, Suryapramata H, Luca G, Börmer C, Dille J, Kallmeyer K, et al. Folate therapy and in-stent restenosis after coronary stenting. N Engl J Med 2004; 350:2673-2681.
30. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326:1419.